{"log_id": 1780426660360469747, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 1e-06, "average": 0.999127, "min": 0.998274}, "location": {"width": 51, "top": 255, "height": 26, "left": 248}, "words": "鼻衄"}, {"probability": {"variance": 0.000353, "average": 0.974786, "min": 0.956}, "location": {"width": 21, "top": 256, "height": 20, "left": 517}, "words": "<1"}, {"probability": {"variance": 0.000401, "average": 0.992902, "min": 0.902264}, "location": {"width": 381, "top": 284, "height": 23, "left": 214}, "words": "美国国立癌症研究所不良事件常用术语标准3.0版"}, {"probability": {"variance": 2.1e-05, "average": 0.997715, "min": 0.974361}, "location": {"width": 729, "top": 305, "height": 27, "left": 215}, "words": "除了在“皮肤和皮下组织异常”中报告的皮疹以外,每个治疗组各有3例受试者在“感染和传染"}, {"probability": {"variance": 0.000502, "average": 0.991512, "min": 0.895096}, "location": {"width": 361, "top": 331, "height": 25, "left": 203}, "words": "害”中报告皮疹;以上无1例达到3级或4级水平"}, {"probability": {"variance": 0, "average": 0.999711, "min": 0.99883}, "location": {"width": 418, "top": 379, "height": 30, "left": 207}, "words": "上述研究的特定实验室检查异常列于下表"}, {"probability": {"variance": 3.2e-05, "average": 0.995949, "min": 0.978656}, "location": {"width": 470, "top": 438, "height": 32, "left": 203}, "words": "表8:特定的实验室检查异常(EGF30008试验)"}, {"probability": {"variance": 1.7e-05, "average": 0.99599, "min": 0.988752}, "location": {"width": 260, "top": 470, "height": 27, "left": 346}, "words": "拉帕替尼1500mg/天+来曲"}, {"probability": {"variance": 3.3e-05, "average": 0.995222, "min": 0.984263}, "location": {"width": 168, "top": 467, "height": 29, "left": 686}, "words": "来曲唑2.5mg/天"}, {"probability": {"variance": 4.5e-05, "average": 0.993365, "min": 0.980034}, "location": {"width": 113, "top": 503, "height": 26, "left": 420}, "words": "唑2.5mg/天"}, {"probability": {"variance": 0.00842, "average": 0.967733, "min": 0.576641}, "location": {"width": 693, "top": 530, "height": 33, "left": 206}, "words": "肝功能参数所有等3级4级所有等级”3级4级"}, {"probability": {"variance": 0.050596, "average": 0.846668, "min": 0.409869}, "location": {"width": 29, "top": 564, "height": 149, "left": 377}, "words": "级%42"}, {"probability": {"variance": 0, "average": 0.999954, "min": 0.999936}, "location": {"width": 106, "top": 594, "height": 26, "left": 483}, "words": "%%"}, {"probability": {"variance": 0, "average": 1, "min": 1}, "location": {"width": 28, "top": 593, "height": 26, "left": 673}, "words": "%"}, {"probability": {"variance": 0, "average": 0.999996, "min": 0.999996}, "location": {"width": 24, "top": 595, "height": 22, "left": 872}, "words": "%"}, {"probability": {"variance": 0, "average": 0.970021, "min": 0.970021}, "location": {"width": 39, "top": 628, "height": 23, "left": 245}, "words": " AST"}, {"probability": {"variance": 2.1e-05, "average": 0.994269, "min": 0.989666}, "location": {"width": 22, "top": 629, "height": 21, "left": 672}, "words": "36"}, {"probability": {"variance": 0, "average": 0.993259, "min": 0.993259}, "location": {"width": 40, "top": 661, "height": 21, "left": 249}, "words": " ALT"}, {"probability": {"variance": 0, "average": 0.999062, "min": 0.998755}, "location": {"width": 23, "top": 659, "height": 22, "left": 674}, "words": "35"}, {"probability": {"variance": 0, "average": 0.999904, "min": 0.999826}, "location": {"width": 94, "top": 690, "height": 27, "left": 220}, "words": "总胆红素"}, {"probability": {"variance": 0.000129, "average": 0.995573, "min": 0.952426}, "location": {"width": 388, "top": 723, "height": 25, "left": 218}, "words": "美国国立癌症研究所不良事件常用术语标准3.0版"}, {"probability": {"variance": 0, "average": 0.999609, "min": 0.998982}, "location": {"width": 143, "top": 777, "height": 27, "left": 205}, "words": "重要不良反应"}, {"probability": {"variance": 6.1e-05, "average": 0.996113, "min": 0.96287}, "location": {"width": 866, "top": 828, "height": 34, "left": 206}, "words": "左室射血分数降低:由于HER2(ErbB2)抑制剂可能有心脏毒性,临床试验中大约每间"}, {"probability": {"variance": 0.010372, "average": 0.96152, "min": 0.480666}, "location": {"width": 832, "top": 861, "height": 29, "left": 205}, "words": "隔8周监测一次LVEF。LVEF降低是指左室心功能的症状或体征加重且≥3级(NCI"}, {"probability": {"variance": 0.000468, "average": 0.994261, "min": 0.868612}, "location": {"width": 874, "top": 891, "height": 28, "left": 208}, "words": " CTCAE)或左室射血分数与基线相比降低≥20%,低于所属机构正常范围下限。198例接"}, {"probability": {"variance": 0.000118, "average": 0.995859, "min": 0.941622}, "location": {"width": 870, "top": 922, "height": 28, "left": 207}, "words": "受拉帕替尼/卡培他滨联合治疗的患者中,3例出现2级LVEF不良反应,1例出现3级"}, {"probability": {"variance": 0.000715, "average": 0.992057, "min": 0.848418}, "location": {"width": 882, "top": 952, "height": 28, "left": 203}, "words": "LVEF不良反应。654例接受拉帕替尼/来曲唑联合治疗的患者中,26例患者出现1级或"}, {"probability": {"variance": 0.000489, "average": 0.99306, "min": 0.897471}, "location": {"width": 636, "top": 982, "height": 31, "left": 204}, "words": "2级LVEF不良反应,6例患者出现3级或4级LVEF不良反应"}, {"probability": {"variance": 7e-06, "average": 0.998721, "min": 0.986996}, "location": {"width": 515, "top": 1037, "height": 34, "left": 205}, "words": "肝毒性:曾经有使用拉帕替尼时出现肝毒性的报告"}, {"probability": {"variance": 0.003355, "average": 0.989316, "min": 0.637305}, "location": {"width": 866, "top": 1095, "height": 31, "left": 206}, "words": "间质性肺病/肺炎:拉帕替尼单药治疗或与其他化疗药物联合时曾有间质性肺病和肺炎"}, {"probability": {"variance": 0, "average": 0.999734, "min": 0.999475}, "location": {"width": 71, "top": 1131, "height": 26, "left": 207}, "words": "的报告"}, {"probability": {"variance": 0, "average": 0.984231, "min": 0.984231}, "location": {"width": 96, "top": 1181, "height": 27, "left": 846}, "words": " GUANGDONG"}, {"probability": {"variance": 4.8e-05, "average": 0.995877, "min": 0.983846}, "location": {"width": 222, "top": 1185, "height": 96, "left": 808}, "words": "华润广东"}, {"probability": {"variance": 0, "average": 0.478943, "min": 0.478943}, "location": {"width": 23, "top": 1195, "height": 21, "left": 948}, "words": " ppp"}, {"probability": {"variance": 9e-06, "average": 0.997731, "min": 0.991847}, "location": {"width": 118, "top": 1218, "height": 27, "left": 208}, "words": "上市后经验"}, {"probability": {"variance": 0.014486, "average": 0.944353, "min": 0.518743}, "location": {"width": 864, "top": 1256, "height": 47, "left": 205}, "words": "拉帕替尼批准上市后发现了以下不良反应。由于这些反应是不律的反群发"}, {"probability": {"variance": 0.006637, "average": 0.98023, "min": 0.519532}, "location": {"width": 821, "top": 1302, "height": 31, "left": 204}, "words": "报告的,因此并不一定能可靠地估计其发生率,也不能确定与物暴露的因果头"}, {"probability": {"variance": 3e-06, "average": 0.998732, "min": 0.995052}, "location": {"width": 444, "top": 1358, "height": 35, "left": 207}, "words": "免疫系统异常:过敏反应包括速发型过敏性"}, {"probability": {"variance": 1e-06, "average": 0.999301, "min": 0.995137}, "location": {"width": 515, "top": 1416, "height": 36, "left": 207}, "words": "皮肤和皮下组织异常:指(趾)甲异常包括甲沟炎"}, {"probability": {"variance": 0, "average": 0.999848, "min": 0.999562}, "location": {"width": 94, "top": 1478, "height": 32, "left": 215}, "words": "【禁忌】"}], "language": 3}